Citation Impact
Citing Papers
Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators
2006 Standout
Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
2019
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Reactive Oxygen Species and the Central Nervous System
1992 Standout
Mitochondrial Dysfunction in Neurodegeneration
1997
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β
2020
The gut microbiota, bacterial metabolites and colorectal cancer
2014 Standout
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
1998 StandoutNature
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter
1999
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
2015 Standout
Radical formation site of cerebral complex I and Parkinson's disease
1995
Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity
1991
The changing landscape of atherosclerosis
2021 StandoutNature
Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice
2003 StandoutNobel
Mitochondria Are a Major Source of Paraquat-induced Reactive Oxygen Species Production in the Brain
2007 Standout
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Mitochondrial control of cell death
2000 Standout
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Alpha-lipoic acid as a biological antioxidant
1995 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
1992
Oxidative stress in Parkinson's disease
2003 Standout
Quantitative autoradiographic distribution of [3H]-MPTP binding in the brains of superoxide dismutase transgenic mice
1991
Type 2 diabetes
2017 Standout
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Hydrogen sulfide inhibits MPP+-induced apoptosis in PC12 cells
2009
Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease
1992
Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease
1999
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease
2004
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
Mitochondrial Complex I Deficiency in Parkinson's Disease
1990 Standout
Oxidative stress and neurodegeneration: where are we now?
2006 Standout
New sensing mechanisms for design of fluorescent chemosensors emerging in recent years
2011 Standout
Oxygen free radicals and Parkinson's disease
1991
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
2000 Standout
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
1993
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Parkinson's Disease
2003 Standout
Reactive Oxygen and Nitrogen Species: Weapons of Neuronal Destruction in Models of Parkinson's Disease
2005
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Oxidants, antioxidants, and the degenerative diseases of aging.
1993 Standout
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling
2011 Standout
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity
1992
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
2003
The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model
2003
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Fluorescence Lifetime Measurements and Biological Imaging
2010 Standout
Diabetic Cardiomyopathy
2018 Standout
Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine
2000 Standout
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
Heteroarylalanines
1997
Spectroscopy and Femtosecond Dynamics of Excited-State Proton Transfer Induced Charge Transfer Reaction
2008
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia
2013
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
1993 StandoutScience
Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease
1993
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Toxicity of Polyamines and Their Metabolic Products
2013
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
Synthesis of Heterocycles from Alkyl 3-(Dimethylamino)propenoates and Related Enaminones
2004 Standout
Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
2015
Oxidative stress in neurodegeneration: cause or consequence?
2004 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
Molecular Genetics of Attention-Deficit/Hyperactivity Disorder
2005 Standout
Works of Dale E. Sharp being referenced
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro
1988
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Synthesis of benzothiazoles. .alpha.-Amino-(4-hydroxy-6-benzothiazolyl)propionic acid
1980
Metabolism and Distribution of [2,3-14C]Acrolein in Sprague-Dawley Rats
1998
Synthes is ofo-Aminothiophenois
1980